MicroPort NeuroTech Limited ((HK:2172)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MicroPort NeuroTech Limited is conducting a clinical study titled ‘A Prospective, Multi-Center, Open-Label, Superiority, Randomized, Controlled Registration Trial of the Rapamycin Neurovascular Balloon Catheter for the Treatment of Symptomatic Cerebral Atherosclerotic Stenosis’. The study aims to evaluate whether the drug-coated balloon (DCB) is superior to the conventional balloon in treating cerebral atherosclerotic stenosis, a condition that narrows the arteries in the brain.
The intervention being tested is the Rapamycin Neurovascular Balloon Catheter, a drug-coated device designed to treat symptomatic cerebral atherosclerotic stenosis. It is compared against a conventional balloon to assess effectiveness.
This interventional study employs a randomized, parallel assignment model without masking, focusing primarily on treatment. Participants are allocated randomly to either the experimental group using the Rapamycin balloon or the control group using the conventional balloon.
The study began on November 8, 2024, which is also the date of the last update. Although the primary completion and estimated completion dates are not specified, the study is currently enrolling by invitation, indicating ongoing progress.
The outcome of this study could significantly impact MicroPort NeuroTech’s stock performance by potentially enhancing its market position if the Rapamycin balloon proves superior. Investors should watch for updates, as successful results may influence industry dynamics, particularly in the neurovascular device sector.
The study is ongoing, with further details available on the ClinicalTrials portal.